Mapping the experiences of adult cancer patients receiving chimeric antigen receptor T-cell (CAR-T) therapy: A scoping review protocol.

ABSTRACT:

Introduction

Chimeric antigen receptor T-cell (CAR T) therapy is an advancement in cancer treatments, particularly for patients with haematological malignancies who have exhausted conventional therapies like chemotherapy and stem cell transplant. CAR-T therapy involves genetically engineering a patient's own T-cells to attack cancer cells. The development of CAR-T therapy increased survival rates in 30% to 80% of patients. Due to its novelty, CAR-T therapy can present unforeseen challenges that prolong the experience of living with cancer and its treatment journey. While CAR-T cell therapies have the potential to be curative, these innovative treatments are often accompanied by a significant symptom burden, primarily cytokine release syndrome (CRS) and immune effector cell associat

SUBMITTER: Girleanu I 

PROVIDER: S-EPMC12680201 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature